3.01
+0.01(+0.33%)
Currency In USD
| Previous Close | 3 |
| Open | 3.01 |
| Day High | 3.01 |
| Day Low | 2.96 |
| 52-Week High | 14.82 |
| 52-Week Low | 2.01 |
| Volume | 6,183 |
| Average Volume | 19,079 |
| Market Cap | 3.99M |
| PE | -0.23 |
| EPS | -13.07 |
| Moving Average 50 Days | 3.41 |
| Moving Average 200 Days | 3.97 |
| Change | 0.01 |
If you invested $1000 in Galecto, Inc. (GLTO) since IPO date, it would be worth $8.03 as of September 08, 2025 at a share price of $3.01. Whereas If you bought $1000 worth of Galecto, Inc. (GLTO) shares 3 years ago, it would be worth $46.67 as of September 08, 2025 at a share price of $3.01.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Galecto to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 06, 2025 1:00 PM GMT
BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team wil
Galecto Reports Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Nov 01, 2024 12:30 PM GMT
- Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge Medicines - Appointed Dr. Amy Wec
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler
GlobeNewswire Inc.
Oct 15, 2024 12:30 PM GMT
BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board